Dr. Mark DOLEV is one of Israel’s leading and most sought-after neurologists. Doctor of Medicine (MD), Chief of the Department of Neurorehabilitation, Deputy Director of the Multiple Sclerosis Center.
He specializes in the study, diagnosis and treatment of inherited and acquired neurodegenerative diseases, particularly the treatment of multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, primary lateral sclerosis, and spinal muscular atrophy.
Mark Dolev is a world-renowned physician with more than 20 years of successful clinical practice in major medical institutions in Israel. He is a renowned specialist in such areas as therapy of vascular diseases of the nervous system, inflammatory diseases of the central and peripheral nervous system, demyelinating diseases of the CNS, as well as treatment of traumas of the nervous system and their consequences. Possesses unique techniques for rehabilitation.
Using an individualized, comprehensive approach and innovative treatment methods, Dr. Dolev has achieved significant and sustained improvement in thousands of patients with neurological disorders. Brilliantly prevents the occurrence of exacerbations.
Dr. Dolev’s key area of professional interest is the study and treatment of patients with multiple sclerosis. He actively uses in his daily practice for the therapy of multiple sclerosis modern immunomodulatory drugs, which can slow down the development of the disease and the appearance of new neurological symptoms, as well as significantly reduce disability.
Dr. Dolev’s recommendations help correct a patient’s diagnosis and achieve the highest rates of successful treatment.
Mark Dolev is an active researcher in the treatment of neurodegenerative diseases and studies autoimmune mechanisms of disease. The doctor pays great attention to the study of the effectiveness of modern drugs. He has published numerous scientific articles on problems in his field of medicine in the most prestigious medical journals.
He speaks three languages fluently: Russian, English and Hebrew.